While this may be in part due a higher incidence of BCR/TLR alterations in PCNSL such as MYD88, it is important to note that even PCNSL patients without obvious genomic alterations in the BCR pathway demonstrate ibrutinib response [60]. Here, MYD88 is linked to primary central nervous system lymphoma.